The Ohio State University
Columbus, Ohio, 43211, United States
NCT Number: NCT00678834
Levels of tocotrienol in human tissues following supplementation is not currently known. The objective of this present study is to determine the levels of this form of vitamin E in the human tissues such as skin, heart, lung, liver, adipose tissue, Brain and cerebrospinal fluid (CSF) following oral supplementation
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Early Phase 1
Columbus, Ohio, 43211, United States
In nature, there are eight members in the vitamin E family: a-, b-, g- and d-TCP, and a-, b-, g- and d-tocotrienol (TCT). Vitamin E research has developed highly asymmetrically. Out of the 25,000+ papers on vitamin E in the PubMed, 99% deal with tocopherols. Recent research has demonstrated the lack of cancer-preventive effects and potential adverse health consequences of tocopherol (6). As a result, more attention has been turned towards non-tocopherol forms of vitamin E (16). Palm oil represents a major source of natural TCT. TCT possess powerful neuroprotective, antioxidant, anti-cancer and cholesterol lowering properties that often differ from the properties of TCP (15).
During the last five years, our and other laboratories have reported several striking beneficial properties of tocotrienols in experimental settings. One major concern that limits enthusiasm for tocotrienol for humans is the report that the vitamin E transporting protein, tocopherol-transport protein (TTP), has a very low affinity to transport tocotrienol. Using TTP-knock out mice, we have recently demonstrated that oral TCT is effectively carried to vital organs and that such transport can take place independent of TTP. With that background, the purpose of this project is to test the hypothesis that orally supplemented tocotrienol reaches the vital organs of humans.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Aim 1 Surgical candidate with a surgery schedule date with a time period of 4-24 weeks (<4 weeks will be excluded; last dose until 24h before surgery) In Aim 1 we expect to have patients, with diverse co-morbidity and medication conditions.
Patient Selection: Because of limitation in obtaining healthy human tissues (as in Aim 2), we plan to obtain these tissues from patients who are scheduled for the following surgeries for subjects in group one:
Heart Heart Transplant Heart Failure- Biopsy taken from diseased heart Lung Lung Transplant, Lung-wedge/resection, Lobectomy Cancer- Tissue sample taken from removed lung or resected portion of lung Liver Liver Transplant, Biopsy, Resection Hepatic Malignancy- Biopsy taken from resected portion of liver Adipose Tissue Panniculectomy Excessive Tissue of the Abdomen Brain & CSF Epilepsy Excised brain tissue and cerebrospinal fluid
To ensure higher enrollment we are not controlling for age of subjects as long as the subjects are 21 years of age or older.
Inclusion criteria
Aim 1:
Inclusion criteria
Aim 2:
Exclusion criteria
Aim 1:
Exclusion criteria
Aim 2:
200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
200 mg to take orally two times a day (400 mg a day).
200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
Time frame: After at least 1 month of supplementation
Chandan K Sen
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00610051
End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
Vienna, Austria
View Trial DetailsNCT05045794
Digestive System Diseases, End Stage Liver Disease
San Bernadino, California, United States
View Trial DetailsNCT07639502
Body Weight, Morbid Obesity
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06199635
Body Weight, Morbid Obesity
Santiago, Huechuraba, Región Metropolitana, Chile
View Trial Details